Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device

LockeT recorded fewer access-site complications and device failures than Perclose in the 172-patient comparison.

Rhea-AI Summary

Catheter Precision, a wholly owned subsidiary of Flyte Aviation (VJET), announced publication of a comparative study evaluating its LockeT device.

The 172-patient, peer-reviewed study compared LockeT with Abbott’s Perclose after large bore venous access for electrophysiologic procedures. Published in The Journal of Interventional Cardiology, it reported cumulative access-site complications of 1.2% with LockeT versus 9.3% with Perclose. Device failure rates were 0.0% versus 4.7%, respectively. Both methods produced similar times to hemostasis, or stopping bleeding, and similar rates of same-day patient discharge.

2 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Moderate pointLockeT’s cumulative access-site complications were 1.2%, compared with 9.3% for Perclose in the comparative study.
• Minor pointLockeT’s device failure rate was 0.0%, compared with 4.7% for Perclose.

Negative

• None.

Argus 15 min delay 5 alerts

-1.81% vs previous close $0.69 last price 0.5x rel. volume Open Argus

Details

Market Reaction – VJET

$0.66 – $0.75 Day Range

$1.45M Mkt Cap at Last Price

On Oct 22, the day this news came out, the latest delayed price for VJET is 1.81% below the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $0.69.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Study size: 172 patients Access-site complications: 1.2% vs. 9.3% Device failure rate: 0.0% vs. 4.7%

Study size

172 patients

Peer-reviewed comparative study

Access-site complications

1.2% vs. 9.3%

LockeT vs. Perclose

Device failure rate

0.0% vs. 4.7%

LockeT vs. Perclose

Key Terms

large bore venous access, suture-mediated closure system, hemostasis, vascular closure device

4 terms

large bore venous access medical

"following large bore venous access."

A type of medical vascular access that uses a wide-diameter catheter or sheath placed into a central vein (typically the femoral, jugular, or subclavian vein) to allow passage of large instruments, devices, or high-volume blood flow. It is used when procedures require delivery or removal of bulky devices (for example mechanical circulatory support, large-bore catheters, or aspiration equipment) and carries specific procedural considerations such as greater risk of bleeding, need for imaging guidance during insertion, and often a larger or longer closure strategy after removal.

suture-mediated closure system medical

"versus suture-mediated closure system after large bore venous access"

A suture-mediated closure system is a medical device used to close holes in blood vessels—most commonly the femoral artery—created during catheter-based procedures. The device delivers one or more stitches (sutures) through the vessel wall from the skin surface to cinch the puncture site closed, allowing faster haemostasis than manual compression; it usually leaves no bulky implant inside the vessel. Effectiveness depends on correct placement and vessel anatomy, so operators must deploy it under appropriate procedural conditions and it is an alternative to manual pressure or plug-based closure methods.

hemostasis medical

"similar results for time to hemostasis"

Hemostasis is the body’s process for stopping bleeding, using a coordinated set of responses that form clots and seal damaged vessels—think of it as the body's natural emergency patch and repair crew. It matters to investors because drugs, medical devices, and diagnostics that influence hemostasis can affect patient outcomes, regulatory approval paths, and market demand for treatments of bleeding disorders or clot-related conditions, so advances or safety issues can materially impact company value.

vascular closure device medical

"against a traditional internal vascular closure device"

A medical device used to seal a blood vessel puncture created during catheter-based procedures, most commonly after arterial or venous access in the groin or wrist. Vascular closure devices work by applying a mechanical closure (suture, clip), implanting a plug or collagen sponge, or deploying bioabsorbable materials at the access site to stop bleeding and support tissue healing; some leave a small implant while others are fully absorbed. They are intended to shorten the time to hemostasis and bed rest compared with manual compression, but can fail or cause local complications such as bleeding, infection, or vessel injury.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT MILL, S.C, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal vascular closure device (VCD) following large bore venous access.

The 172-patient peer-reviewed study, titled "Vascular closure with a suture retention device versus suture-mediated closure system after large bore venous access for electrophysiologic procedures," was published in The Journal of Interventional Cardiology (JICE), a premier publication dedicated to original electrophysiology research and advanced ablation techniques.

The clinical data demonstrated the superior safety and efficacy of the LockeT device compared to Perclose, a leading internal VCD, manufactured and sold by Abbott. Key findings from the study include:

• Fewer Complications: LockeT reduced cumulative access-site complications to just 1.2%, compared to 9.3% with Perclose.
• Zero Device Failures: The LockeT device achieved a 0.0% failure rate, outperforming the VCD's 4.7% failure rate.
• Equivalent Efficiency: Both methods delivered similar results for time to hemostasis and rates of same-day patient discharge.
  
  

"We are thrilled with the outcomes of this study," said David Jenkins, CEO of Catheter Precision. "These findings validate what we have believed all along: LockeT matches the efficiency of a VCD in achieving hemostasis and enabling same-day discharge, while providing the critical advantages of fewer complications and zero device failures. In a clinical setting, device failures may directly cause access-site complications, forcing hospitals to bear the added costs of opening replacement devices, extending patient stays, and increasing monitoring times."

About LockeT
Catheter Precision's LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval, now selling in the US, Europe and South America.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

About Flyte Aviation, Inc.
Flyte Aviation, Inc. is a holding company for Fly Flyte and Ponderosa Air. Fly Flyte is a technology-enabled private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient private air travel throughout the United States and select international markets. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary, Ponderosa Air, LLC, Flyte is delivering a faster, safer and more convenient private aviation experience.

For more information, visit www.flyflyte.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks.

Contact
IR@FlyFlyte.com
(800) 763-0904

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Catheter Precision’s LockeT study find compared with Abbott’s Perclose?

The study reported access-site complications of 1.2% with LockeT versus 9.3% with Perclose, and device failure rates of 0.0% versus 4.7%, respectively. The 172-patient comparison found similar times to stopping bleeding and similar rates of same-day patient discharge.